Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "generic"

798 News Found

Dr. Reddy's Laboratories launches Sapropterin Dihydrochloride powder for oral solution in US
News | April 08, 2021

Dr. Reddy's Laboratories launches Sapropterin Dihydrochloride powder for oral solution in US

Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose


GlaxoSmithKline approves sale of Vemgal plant
News | April 05, 2021

GlaxoSmithKline approves sale of Vemgal plant

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS


Govt. receives 215 applications for the 36 products under PLI scheme
News | March 13, 2021

Govt. receives 215 applications for the 36 products under PLI scheme

174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.


NATCO receives approval for Everolimus tablets for the US market
News | March 09, 2021

NATCO receives approval for Everolimus tablets for the US market

NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.


Pharma sector will be $130 billion strong by 2030: EY-FICCI paper
News | March 04, 2021

Pharma sector will be $130 billion strong by 2030: EY-FICCI paper

The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades


Pharma 4.0: Pandemic pushed reluctant pharma companies to adopt advanced technologies
News | March 04, 2021

Pharma 4.0: Pandemic pushed reluctant pharma companies to adopt advanced technologies

Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.


Lupin launches penicillamine tablets USP
News | March 04, 2021

Lupin launches penicillamine tablets USP

Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).


Piramal Enterprises cashing in on opportunities: ICICI Securities
News | March 02, 2021

Piramal Enterprises cashing in on opportunities: ICICI Securities

PEL will explore the PLI scheme and apply if its beneficial.


Accelerated growth in pharma depends on the right policies: Experts
News | March 01, 2021

Accelerated growth in pharma depends on the right policies: Experts

A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders


Pharma stalwarts demystify COVID-19 impact on industry
News | March 01, 2021

Pharma stalwarts demystify COVID-19 impact on industry

Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.